Trial Profile
A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic Metastases.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs TKM PLK1 (Primary)
- Indications Breast cancer; Colorectal cancer; Liver cancer; Liver metastases; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 25 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 25 Jun 2012 Additional lead trial investigator (Thomas S Uldrick) identified and actual patients number (1) added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Status changed from recruiting to discontinued according to a Tekmira media release. Proof-of-concept of LNP technology was established based on interim results from Alnylam's programmes that utilise Tekmira's LNP technology.